The molecular diagnostics firm revealed it has signed a Memorandum of Understanding with a Saudi Arabian partner to potentially create a joint venture aimed at developing and distributing its Co-Dx™ ...

While financial markets across the globe are tumbling on concerns that the rapidly spreading coronavirus will inflict more damage on the global economy than previously anticipated, a few “coronavirus ...

CODX received its first issued patent for the Co-Dx PCR platform from the Australian Patent Office. CODX's patent covers the PCR Pro instrument and proprietary test cups for point-of-care use. CODX is ...

Specializing in molecular diagnostic polymerase chain reaction (PCR) tests, Co-Diagnostics (NASDAQ:CODX) represents an extremely relevant business in the new normal. Early this morning, the company ...

CoDiagnostics, Inc. (CODX Quick Quote CODX - Free Report) shares ended the last trading session 9.7% higher at $8.62. The jump came on an impressive volume with a higher-than-average number of shares ...

In this article we will analyze whether Co-Diagnostics, Inc. (NASDAQ:CODX) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas.

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Co-Diagnostics (CODX) is a stock that can certainly grab the attention of many ...

CoDiagnostics, Inc. (CODX) closed at $25.73 in the latest trading session, marking a -1.61% move from the prior day. This move lagged the S&P 500's daily gain of 0.06%. Meanwhile, the Dow gained 0.17% ...

Co-Diagnostics will put out its first-quarter earnings after the close this evening Biotech Co-Diagnostics Inc (NASDAQ:CODX) has been in the spotlight recently as one of the companies producing ...